Compare JJSF & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | ARDX |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 996.8M |
| IPO Year | 1995 | 2014 |
| Metric | JJSF | ARDX |
|---|---|---|
| Price | $89.88 | $3.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $140.00 | $15.14 |
| AVG Volume (30 Days) | 230.3K | ★ 4.7M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | $2,607,000.00 |
| Revenue This Year | $0.30 | $37.75 |
| Revenue Next Year | $1.70 | $34.24 |
| P/E Ratio | $45.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $68.87 | $3.73 |
| 52 Week High | $114.06 | $8.40 |
| Indicator | JJSF | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 25.38 |
| Support Level | $88.35 | N/A |
| Resistance Level | $95.69 | $6.47 |
| Average True Range (ATR) | 2.50 | 0.17 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 55.29 | 3.14 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.